"Merck's Q1 2026 revenue reached $16.29 billion, growing 4.87% year over year and beating consensus by 2.77%. Non-GAAP EPS of -$1.28 topped the -$1.47 estimate, reflecting a 13.15% beat despite a $9.0 billion acquisition charge."
"Management raised full-year guidance to $65.80 billion to $67 billion in revenue and $5.04 to $5.16 in non-GAAP EPS, indicating confidence in the company's operational performance."
"The bull thesis rests on pipeline depth, with the CEO stating, 'we are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas.'"
Merck reported Q1 2026 revenue of $16.29 billion, exceeding expectations and showing year-over-year growth. Despite a significant acquisition charge impacting earnings, KEYTRUDA's strong performance contributed to a positive outlook. The company raised its full-year revenue guidance, and analysts project a price target of $135.70, suggesting a 24.29% upside. The stock has experienced volatility, but a robust pipeline and upcoming catalysts support a bullish sentiment among investors, with a consensus of 62% bullish ratings.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]